News Search Results
May 29, 2025, 12:01 ET NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA
specialty therapies where there is an unmet need. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. ST is a member of the World Orphan Drug Alliance
More news about: Specialised Therapeutics
May 29, 2025, 08:00 ET NeuLogiq® Platform Confirms Electrophysiological Marker of Target Engagement in Patients with Major Depressive Disorder
in Alzheimer's dementia," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. "Over time, NeuLogiq has evolved to be used across CNS conditions including multiple psychiatric disorders. Collectively, these data presented at ASCP confirm that the NeuLogiq Platform has the potential
More news about: Cumulus Neuroscience
May 29, 2025, 08:00 ET Diakonos Oncology to Present Phase I Results of Dubodencel (DOC1021), a Double-Loaded Dendritic Cell Therapy for Glioblastoma, at the ASCO 2025 Annual Meeting
SessionSession Title: Central Nervous System TumorsTrack: Central Nervous System TumorsSub Track: Primary CNS Tumors–GliomaSession Date and Time: May 31, 2025, 3:00 PM-4:30 PM CDTLocation: Room
More news about: Diakonos Oncology
May 29, 2025, 07:30 ET Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025
in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.Because of the risks of CNS depression and abuse and misuse,
More news about: Jazz Pharmaceuticals plc
May 29, 2025, 07:01 ET Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor
brain-penetrant, selective inhibitor of TYK2 and JAK1, BHV-8000 has the potential to modulate critical inflammatory pathways, in the periphery and in the CNS, that results in neuronal loss and functional decline in people living with PD." The pivotal Phase 2/3 study is a randomized, double-blind,
More news about: Biohaven Ltd.
May 28, 2025, 12:58 ET ENA Names Harriet Hawkins 2025 Judith C. Kelleher Award Recipient
Georgia Clinical Nurse Specialist Award:Dawn Zakzesky, MSN, RN, CNS-BC, CEN, of Wisconsin Crisis Response Team Award:Children's Mercy Adele Hall Team, of
More news about: Emergency Nurses Association
May 28, 2025, 09:00 ET 1Cell.Ai Completes CLIA Validation Study of OncoIncytes 1080-Gene NGS Panel
pipeline, the system provides scalable variant classification and interpretation across diverse cancer types, including lung, breast, GI, ovarian, and CNS malignancies. "This milestone enables the translational use of OncoIncytes 1080-gene NGS panel in exploratory biomarker discovery and patient
More news about: 1Cell.Ai
May 28, 2025, 09:00 ET Mitsubishi Tanabe Pharma America Announces U.S. FDA Acceptance of New Drug Application Resubmission for Investigational ND0612 for the Treatment of Motor Fluctuations in Parkinson's Disease
combination therapies and technologies. NeuroDerm is an integrated pharmaceutical and medical technology company developing central nervous system (CNS) product candidates. For additional information, please visit NeuroDerm's website at
More news about: Mitsubishi Tanabe Pharma America
May 28, 2025, 08:08 ET NCCN Recognizes Outstanding Contributions in Oncology with 2025 Awards
at University of Alabama at Birmingham (UAB)—Chair of the NCCN Guidelines Panel for Central Nervous System Cancers (CNS) since 2017 and Member since 2013—also received a 2025 Excellence in Engagement Award. Dr. Nabors was also honored for his commitment to NCCN's
More news about: National Comprehensive Cancer Network
May 27, 2025, 08:30 ET Cipla North America Partners with American Lung Association for 2025 LUNG FORCE Walk to Champion Respiratory Health
North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms
More news about: Cipla
May 27, 2025, 08:30 ET STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer
discovery of breakthrough small molecule drugs that precisely reprogram cells through RNA biology for the treatment of cancer, inflammation, viruses and CNS diseases. STORM's lead product, STC-15, is the first RNA modifying enzyme inhibitor to enter human clinical development. STC-15 is currently being
More news about: STORM Therapeutics
May 27, 2025, 02:00 ET MEXC Ventures at the Forefront of Korea's Blockchain-AI University Innovation Showcase
university-driven ideathon. MEXC Ventures served as a premier sponsor of the blockchain track, alongside the Korea Internet & Security Agency (KISA), LG CNS, and Tether. The AI track, organized under the same program, was supported by Koscom and Toss, contributing to a diverse and collaborative innovation
More news about: MEXC Ventures
May 27, 2025, 02:00 ET MEXC Ventures at the Forefront of Korea's Blockchain-AI University Innovation Showcase
university-driven ideathon. MEXC Ventures served as a premier sponsor of the blockchain track, alongside the Korea Internet & Security Agency (KISA), LG CNS, and Tether. The AI track, organized under the same program, was supported by Koscom and Toss, contributing to a diverse and collaborative
More news about: MEXC Ventures
May 26, 2025, 17:31 ET Rett Syndrome Market Sees Momentum with Novel Gene and Protein-Targeted Therapies | DelveInsight
introducing a functional MECP2 gene into cells of the central nervous system (CNS). The therapy features an innovative miRNA-Responsive Auto-Regulatory Element (miRARE) technology, which helps regulate MECP2 expression in individual CNS cells, minimizing the risk of overexpression. TSHA-102 has been
More news about: DelveInsight Business Research, LLP
May 26, 2025, 06:06 ET Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025
both GCB and non-GCG subtypes, an important feature. With full BBB penetration and a favorable safety profile, it also shows promise in patients with CNS involvement, who typically confront a poor prognosis." DZD6008: A 4th generation
More news about: Dizal Pharmaceutical
May 25, 2025, 21:00 ET World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial
XellSmart has been dedicated to the development of clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervous system (CNS) diseases that currently lack effective treatment options. Up until now, XellSmart has secured formal approvals from both China's
More news about: XellSmart
May 22, 2025, 21:00 ET Rayakan Prestasi Industri Properti, American Standard dan GROHE dari LIXIL Dukung Asia Pacific International Property & Hotel Awards 2025-2026
Tenggara berhasil meraih penghargaan utama dari LIXIL. Salah satu karya tanah air, yaitu Stone Experience Center karya MM Galleri bersama CNS Designworks dari Indonesia meraih GROHE Luxury Award. Penghargaan ini menyoroti konsep New Luxury,
More news about: Lixil
May 22, 2025, 18:02 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
May 22, 2025, 17:47 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
May 22, 2025, 17:45 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
May 22, 2025, 17:43 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
May 22, 2025, 17:29 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
May 22, 2025, 17:05 ET Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
updated results from a Phase 1/2 study of olomorasib, a potent and highly selective second-generation inhibitor of KRAS G12C with preliminary evidence of CNS activity, in combination with pembrolizumab in patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC) and in combination with
More news about: Eli Lilly and Company
May 22, 2025, 08:00 ET Corundum Neuroscience and Corundum Systems Biology to Host Panel Sessions at First Ever SXSW London
May 22, 2025 /PRNewswire/ -- Corundum Neuroscience (CNS), the neuroscience venture builder and fund, and Corundum Systems Biology (CSB),
More news about: Corundum Neuroscience; Corundum Systems Biology
May 22, 2025, 00:00 ET LG CNS showcases AI-Enhanced 'PerfecTwin ERP Edition' in the U.S. at SAP Sapphire 2025
in ERP and continue to support innovation for global clients," said Hanshin Nae, Senior Vice President of LG CNS Enterprise Solutions Division. About LG CNS LG CNS is a leading Korean AX (AI Transformation) company that continues to pioneer various emerging technologies, including
More news about: LG CNS